ArticleJMIR medical informatics2026
Design Principles for Interactive Dashboards in Drug Safety Surveillance: Design Science Research.
Article in JMIR medical informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adverse drug reactions pose a serious threat to health care, leading to patient harm and substantial economic burden. Dashboards for drug safety surveillance are a valuable tool to tackle it. Objective: This qualitative study aims to develop a dashboard for drug safety tracking with active and iterative involvement of end users. To support dashboard development, we formulate and iteratively refine design principles (DPs) for drug safety dashboards using the affordance theory. Methods: Following a design science research approach, we conducted 3 cycles of iterative design and evaluation involving the end users. Four professional end users (with expertise in drug screening, drug discovery, and data science) and 6 nonprofessional end users (drug consumers) were engaged in the requirements gathering sessions through co-design workshops, usability testing through think-aloud sessions, and heuristic evaluation. Results: The analysis resulted in a set of 8 DPs refined using the prototype's affordances (ie, actionable properties of the dashboard that guide user interaction and interpretation of data). Following themes emerged in the formulation and refinement of DPs: addressing the bootstrap problem through designing for immediate use (DP1a), allowing identification of patterns through visualizing causality while signalizing uncertainty (DP1b), tracking trends for relevant variables (DP1c), implementing user-controlled views (DP2a) and customizable levels of data granularity (DP2b), guiding user's visual attention through spatial layouts (DP2c), designing for higher public value (DP3a) and providing features to support decision-making for varied stakeholders' groups (DP3b). A high-fidelity dashboard prototype for drug safety surveillance was proposed as a result of applying the final set of DPs. Heuristic evaluation of the prototype revealed an overall usability score of 84%. Conclusions: Applying DPs rooted in affordance theory led to a purposeful and user-relevant artifact that can improve understanding of drug safety data and potentially guide decision-making processes for professional users. Our theoretical contribution lies in providing refined DPs, while also demonstrating how affordances can aid dashboard development in pharmacovigilance. Our findings may be applicable to similar health information systems in related domains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.